Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...
We've tested the top AI image generation apps to help you find the one that produces the best results for the lowest price. I’ve been writing about consumer technology and video games for more than a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback